Savient Pharmaceuticals, Inc.
http://www.savientpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Savient Pharmaceuticals, Inc.
China Market For Medtech: Opportunity Or Headache?
Medtech companies have typically seen a “mixed picture of growth” in China in the past year or two, but it is a market that requires ongoing commitment, a panel of experts argued at the MedTech Forum 2024.
What's Next For Phase II ADCs
BMS may have ditched an antibody-drug conjugate partnership with Eisai, but the Phase II pipeline for ADCs remains strong across the industry.
Talc Litigation Attorneys Allege ‘Bad Faith Filings,’ ‘Fraudulent Activities’ By J&J In Bankruptcy
Attorneys for some plaintiffs alleging harm from talc products J&J marketed ask a court to order the firm, along with a subsidiary holding company it created in 2021 to manage its talc liabilities and immediately placed in bankruptcy, to provide emails and other communications among in-house counsel and compel their testimony.
Finance Watch: Alumis Launches IPO In Market Less Receptive Than Expected
Public Company Edition: Alumis grosses $250m after it planned to raise up to $317.7m in its IPO. Also, Zealand adds $1bn in a post-data offering, Tectonic and Eliem close $130.7m and $120m private placements to support recent mergers, and Ginkgo cuts 35% of its workforce.
Company Information
- Other Names / Subsidiaries
-
- Bio-Technology General Corporation
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice